Safety evaluation demonstrates equivalent safety and nutritional profiles for soybean MON 94313, indicating no adverse effects on human, animal, or environmental health.
expression cassettes. The molecular characterisation data and bioinformatics analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between soybean MON 94313 and its conventional counterpart need further assessment, except for methionine and Gly m Bd 28K, which underwent additional evaluation and were found to not raise any safety or nutritional concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the DMO, PAT, FT_T.1 and TDO proteins as expressed in soybean MON 94313 and finds no evidence that the genetic modification would change the overall safety of soybean MON 94313. In the context of this application, the consumption of food and feed from soybean MON 94313 does not represent a nutritional concern in humans and animals, and no post-market monitoring of food/feed is considered necessary. In the case of release of processed soybean MON 94313 material, or accidental spillage of viable GM soybean seeds into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of soybean MON 94313. The GMO Panel concludes that soybean MON 94313 is as safe as its conventional counterpart and the tested non-GM soybean varieties with respect to potential effects on human and animal health and the environment.
No takes yet. Share an insight, caveat, or question.
(GMO) et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: